Long-acting antipsychotics: is what we know really so?
Lancet Psychiatry
.
2021 Aug;8(8):651.
doi: 10.1016/S2215-0366(21)00237-6.
Authors
Lisa Cosgrove
1
,
Barbara Mintzes
2
,
Harold J Bursztajn
3
,
Allen F Shaughnessy
4
Affiliations
1
Counseling Psychology Department and Applied Ethics Center, University of Massachusetts Amherst, Boston, MA, USA.
2
School of Pharmacy and Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
3
Department of Psychiatry, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
4
Department of Family Medicine, Tufts University School of Medicine, Malden, MA 02148, USA. Electronic address: allen.shaughnessy@tufts.edu.
PMID:
34303402
DOI:
10.1016/S2215-0366(21)00237-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Antipsychotic Agents* / adverse effects
Delayed-Action Preparations
Humans
Schizophrenia* / drug therapy
Substances
Antipsychotic Agents
Delayed-Action Preparations